MedTrace Logo

A Study of TIL in Advanced Solid Tumors (CZ)

NCT07294872 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-16

No results posted yet for this study

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs and gene-edited TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Conditions

  • Solid Tumor, Adult

Interventions

BIOLOGICAL

GC101TIL

A tumor sample is resected from each participant and cultured ex vivo to expand the population of Autologous Tumor Infiltrating Lymphocytes Injection (GC101 TIL). After lymphodepletion, patients are infused GC101 TIL.

Sponsors & Collaborators

  • Sichuan Cancer Hospital and Research Institute

    collaborator OTHER

  • Shanghai Juncell Therapeutics

    lead INDUSTRY

Principal Investigators

  • Huangming Hong · Sichuan Cancer Hospital & Institute, Sichuan Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-08
Primary Completion
2026-09-20
Completion
2029-09-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07294872 on ClinicalTrials.gov